Home / Medications

GLP-1 Medications

Every FDA-approved GLP-1 for weight loss in 2026, compared on efficacy, cost, insurance coverage, and side effects. Plus the pipeline drugs coming in the next 12 months.

The short answer
Zepbound
Tirzepatide · Injection
Highest average weight loss of any approved GLP-1. Dual GIP/GLP-1 agonist. Weekly injection.
$299–$499FDA for obesity
Wegovy (injectable)
Semaglutide · Injection
The original obesity-approved GLP-1. Weekly injection. Strong real-world and CV outcome data.
$349/moFDA for obesity
Wegovy Pill
Semaglutide · Daily pill
First oral semaglutide approved for obesity (Jan 2026). Daily pill — no injection.
$149–$299FDA for obesity
Ozempic
Semaglutide · Injection
Approved for type 2 diabetes; often prescribed off-label for weight loss.
$349/moOff-label
Saxenda
Liraglutide · Injection
First-gen GLP-1. Daily injection. Generic now available. Lower efficacy than newer drugs.
$299/mo (generic)FDA for obesity

How to choose a GLP-1 in 2026

Five FDA-approved GLP-1 drugs are commercially available for adult weight management in the U.S. as of April 2026: Zepbound, Wegovy, the Wegovy Pill, Saxenda, and (for diabetes, off-label for weight loss) Ozempic. The right choice depends on how much weight loss you're targeting, whether you have related conditions, what your insurance covers, and your preferences on injections versus oral dosing.

By efficacy

On head-to-head data, tirzepatide (Zepbound) produces about 47% more weight loss than semaglutide 2.4 mg (Wegovy) — the largest efficacy gap in the category. Tirzepatide's dual GIP/GLP-1 mechanism is the mechanistic reason for this advantage; Wegovy and Ozempic act only on GLP-1 receptors.

Approximate mean weight loss from pivotal trials (after 64–72 weeks, at maximum dose):

By cost

Cash-pay brand-name prices in 2026, from cheapest to most expensive:

With commercial insurance coverage and savings cards, all of these drop to $0–$25/month for covered patients. See the GLP-1 insurance coverage guide for plan-by-plan details.

By condition

GLP-1s have expanding FDA indications beyond weight management and diabetes:

What's coming

The 2026–2027 pipeline will reshape this list. Expected approvals:

Safety considerations across the class

All GLP-1s share a common safety profile. Side effects are predominantly gastrointestinal (nausea, diarrhea, constipation, vomiting), dose-related, and concentrated in the first 8–12 weeks after each dose escalation. The GLP-1 side effects guide covers every commonly reported effect and what to do about each.

Serious but uncommon risks include acute pancreatitis, gallbladder disease, and acute kidney injury secondary to dehydration from severe GI side effects. A boxed warning for thyroid C-cell tumors applies across the class; GLP-1s are contraindicated in anyone with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Pregnancy is a contraindication; the American Society of Anesthesiologists recommends holding weekly GLP-1s for one week before elective surgery to reduce aspiration risk.

Frequently asked questions

What are GLP-1 drugs?
GLP-1 receptor agonists are injectable or oral medications that mimic the gut hormone glucagon-like peptide-1. They slow gastric emptying, reduce appetite signaling in the brain, and improve insulin sensitivity. Originally developed for type 2 diabetes, higher doses are now FDA-approved for chronic weight management and produce 10–22% mean weight loss depending on the specific drug.
Which GLP-1 is best for weight loss in 2026?
Zepbound (tirzepatide) produces the most weight loss — 22.5% on average at the 15 mg dose in SURMOUNT-1, and beat semaglutide head-to-head in SURMOUNT-5 (2025). Wegovy (semaglutide 2.4 mg) is the second-most effective and the only GLP-1 with FDA indication for cardiovascular risk reduction in patients with established heart disease.
How much do GLP-1 drugs cost in 2026?
List prices range from $999–$1,349/month. With commercial insurance coverage and savings cards, covered patients typically pay $0–$25/month. Cash-pay options via LillyDirect ($349/month for Zepbound) and NovoCare Pharmacy ($499/month for Wegovy) are the lowest brand-name prices available without insurance.
Does insurance cover GLP-1s for weight loss?
About 60% of commercially insured Americans have some GLP-1 coverage for obesity in 2026. Medicare Part D does not cover GLP-1s for weight management but does cover Wegovy for its cardiovascular indication in qualifying patients. State Medicaid coverage varies from comprehensive to non-existent. See our insurance guide for state-by-state details.
What are the most common GLP-1 side effects?
Nausea, diarrhea, vomiting, constipation, and abdominal pain. These are dose-related, typically mild-to-moderate, and concentrated in the first 8–12 weeks of dose escalation. Slower titration and dietary adjustment resolve most cases. Less common but serious effects include pancreatitis, gallbladder disease, and dehydration-related kidney injury.
Can I take a GLP-1 as a pill instead of an injection?
Yes. The Wegovy Pill (oral semaglutide 25 mg daily) was FDA-approved for chronic weight management in January 2026 and produces ~13.6% weight loss. Rybelsus is the oral semaglutide for diabetes. Orforglipron, a small-molecule oral GLP-1 with Zepbound-level efficacy, is expected to file for FDA approval in 2026.
What happens if I stop taking a GLP-1?
Most patients regain about half of their lost weight within a year of stopping, per the STEP-4 and SURMOUNT-4 trials. Obesity is a chronic condition; guidelines treat GLP-1 therapy as long-term, similar to blood pressure medication. Sustained lifestyle modification may reduce regain but rarely prevents it entirely.

Last reviewed April 2026. Not medical advice. Always consult a healthcare provider before starting any GLP-1 medication.